Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
MDXL Stock Summary
In the News
MediXall Group & Health Karma(R) CEO to Participate in the Healthcare IT Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Wednesday, January 25th
FORT LAUDERDALE, FL / ACCESSWIRE / January 24, 2023 / MediXall Group Inc. (OTCQB:MDXL) ("MediXall"), an innovative healthcare solutions provider, is pleased to announce that MediXall and Health Karma Chief Executive Officer, Travis Jackson has been invited to present at the Healthcare IT Virtual Conference, presented by Maxim Group LLC and hosted by M-Vest, on Wednesday, January 25th, 2023 at 2:45 pm ET. Mr. Jackson will be presenting on a panel focused on "Improving Patient Outcomes & Experiences".
Innovative Healthcare Solutions Provider 'Health Karma' Reports Many Accomplishments To Date This Year
FT. LAUDERDALE, FL / ACCESSWIRE / August 25, 2021 / MediXall Group, Inc. (OTCQB:MDXL), a leading innovative healthcare solutions provider, today provided an update on the growth and accomplishments of its wholly owned subsidiary, Health Karma™ this year. To date, 2021 has been very positive for Health Karma, with the company accomplishing the following: Appointed Experienced Health Insurance Technology Executive Travis Jackson as New Chief Executive Officer of Health Karma.
MediXall Group Announces Appointment of Experienced Health Insurance Technology Executive Travis Jackson as New Chief Executive Officer of Health Karma
FORT LAUDERDALE, FL / ACCESSWIRE / August 17, 2021 / MediXall Group, Inc. (OTCQB:MDXL), an innovative healthcare solutions provider, announced today that healthcare technology executive Travis Jackson has been appointed Chief Executive Officer (CEO)of its wholly-owned subsidiary, Health Karma. Mr. Jackson appointment went effective, August 16th.
MediXall Group Hires Leading PR Firm, TransMedia Group, to Drive Brand Awareness & Media Relations to Propel Health Karma on Its Next Phase of Growth
FORT LAUDERDALE, FL / ACCESSWIRE / August 5, 2021 / MediXall Group, Inc. (OTCQB:MDXL), an innovative healthcare solutions provider, announced that the leading international public relations firm, Transmedia Group, will generate media coverage highlighting the positive impact its wholly owned subsidiary, Health Karma, has had on health and wellness of individuals and employees of businesses nationwide. The PR campaign will focus on Health Karma's success as it enters the next phase of growth and seeks to expand its footprint on healthcare.
MediXall Group Subsidiary Health Karma Mental Health Awareness Campaign Drives Consumer Acquisition
FORT LAUDERDALE, FL / ACCESSWIRE / May 18, 2021 / MediXall Group, Inc. (OTCQB:MDXL) is pleased to report that its wholly owned subsidiary, Health Karma, is experiencing business growth and momentum as it drives new consumer acquisition through its Mental Health Awareness Campaign. Stated Jonathan Martinez, Lead Growth Marketer at Health Karma, "We've seen phenomenal performance with our mental health performance marketing campaigns - the CTR on these campaigns are +38.46% the baseline.
As Big Pharma Continues to Hike Prices, Health Karma, Subsidiary of MediXall Group, Reduces Cost of Prescription Medications
PRESIDENT BIDEN'S AMERICAN FAMILIES PLAN UNVEILED LAST WEDNESDAY DOES NOT INCLUDE PROPOSAL TO CUT PRESRIPTION DRUG PRICES FORT LAUDERDALE, FL / ACCESSWIRE / May 5, 2021 / MediXall Group, Inc. (OTCQB:MDXL) reported today that its subsidiary, Health Karma, is reducing the cost of prescription medications by delivering RX discounts to consumers through the Health Karma online platform. This comes at a critical time as Big Pharma continues to increase medication prices even as individuals are struggling through a pandemic and economic crisis.
MediXall Group Launching New Campaign Through Health Karma in Support of Mental Health Awareness Month
AS COVID-19 STRETCHES INTO A SECOND YEAR, MEDIXALL GROUP PROVIDES ESSENTIAL MENTAL HEALTH SUPPORT FORT LAUDERDALE, FL / ACCESSWIRE / April 29, 2021 / In support of Mental Health Awareness Month, MediXall Group, Inc. (OTCQB:MDXL), reported today that its wholly-owned subsidiary, Health Karma, developed a new campaign in support of mental health awareness month. During the month of May, new users who sign up for Health Karma will receive one free month of Health Karma's total health plan which includes access to a network of licensed therapists to address mental health concerns.
Partner Program Fuels Medixall Group Subsidiary Sales
Wise Health Plans Signs as Partner To Deliver Affordable Healthcare for All FORT LAUDERDALE, FL / ACCESSWIRE / April 27, 2021 / MediXall Group, Inc. (OTCQB:MDXL), an innovative healthcare solutions provider, announced today that its subsidiary, Health Karma, is signing up agencies and brokerage firms as part of its new Health Karma Partner Program geared toward building a multi-tiered sales channel to accelerate market adoption. WISE Health Plans, an insurance brokerage firm located in Utah, has completed the onboarding process, and is preparing to launch a Health Karma marketing campaign to support its mission to deliver affordable healthcare for all.
Technology Giants Flock to Healthcare Arena; MediXall Group Targets Additional Acquisitions
FORT LAUDERDALE, FL / ACCESSWIRE / April 20, 2021 / MediXall Group, Inc. (OTCQB:MDXL), an innovative healthcare solutions provider, announced today that it has targeted key acquisition candidates as it plans to roll out an aggressive acquisition strategy over the next three months. The announcement comes at a time when technology giants are flocking to the healthcare arena as the pandemic has showcased the value of technology in healthcare.
MediXall Group Reports Skyrocketed Conversion Rates for Health Karma Social Media Campaigns
Conversion rates more than double industry standards. FORT LAUDERDALE, FL / ACCESSWIRE / April 14, 2021 / MediXall Group, Inc. (OTCQB:MDXL), an innovative healthcare solutions provider, was pleased to announce today that the Health Karma direct-to-consumer social media campaigns are consistently reporting over 20% conversion rates.
MDXL Financial details
MDXL Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.05 | -0.05 | -0.07 | -0.06 | -0.06 | |
Operating cash flow per share | -0.03 | -0.03 | -0.04 | -0.04 | -0.03 | |
Free cash flow per share | -0.04 | -0.03 | -0.04 | -0.05 | -0.03 | |
Cash per share | 0 | 0.01 | 0.01 | 0 | 0 | |
Book value per share | 0.01 | 0.01 | 0 | 0 | -0.03 | |
Tangible book value per share | 0 | 0 | 0 | -0.01 | -0.04 | |
Share holders equity per share | 0.01 | 0.01 | 0 | 0 | -0.03 | |
Interest debt per share | 0 | 0 | 0 | 0 | 0.03 | |
Market cap | 146.28M | 148.27M | 83.38M | 109.41M | 74.66M | |
Enterprise value | 146.08M | 147.94M | 82.95M | 109.67M | 77.48M | |
P/E ratio | -49.03 | -43.34 | -14.06 | -18.13 | -10.93 | |
Price to sales ratio | 78.73K | 55.22K | 0 | 7.3K | 1.26K | |
POCF ratio | -65.74 | -63.31 | -23.8 | -23.35 | -20.97 | |
PFCF ratio | -58.35 | -62.88 | -23.19 | -23.29 | -20.96 | |
P/B Ratio | 269.41 | 372.76 | 218.33 | -321.69 | -20.35 | |
PTB ratio | 269.41 | 372.76 | 218.33 | -321.69 | -20.35 | |
EV to sales | 78.62K | 55.1K | 0 | 7.31K | 1.31K | |
Enterprise value over EBITDA | -49.01 | -44.15 | -13.99 | -16.8 | -12.33 | |
EV to operating cash flow | -65.65 | -63.17 | -23.68 | -23.41 | -21.76 | |
EV to free cash flow | -58.27 | -62.75 | -23.07 | -23.34 | -21.75 | |
Earnings yield | -0.02 | -0.02 | -0.07 | -0.06 | -0.09 | |
Free cash flow yield | -0.02 | -0.02 | -0.04 | -0.04 | -0.05 | |
Debt to equity | 0 | 0.3 | 0.56 | -0.93 | -0.77 | |
Debt to assets | 0 | 0.13 | 0.13 | 0.28 | 3.27 | |
Net debt to EBITDA | 0.07 | 0.1 | 0.07 | -0.04 | -0.45 | |
Current ratio | 1.95 | 0.9 | 1.01 | 0.28 | 0 | |
Interest coverage | 0 | 0 | 0 | 0 | -25.19 | |
Income quality | 0.75 | 0.68 | 0.59 | 0.76 | 0.52 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 1.56K | 1.28K | 0 | 426.66 | 98.55 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0.66 | |
Intangibles to total assets | 0.48 | 0.38 | 0.27 | 0.4 | 0.66 | |
Capex to operating cash flow | 0.13 | 0.01 | 0.03 | 0 | 0 | |
Capex to revenue | -151.53 | -5.86 | 0 | -0.86 | -0.02 | |
Capex to depreciation | -89.52 | -0.23 | -22.89 | -3.21 | -0.04 | |
Stock based compensation to revenue | 537.01 | 239.57 | 0 | 90.88 | 33.15 | |
Graham number | 0.09 | 0.07 | 0.08 | 0.07 | 0.2 | |
ROIC | -5.18 | -5.4 | -9.24 | -21.84 | 12.18 | |
Return on tangible assets | -7.91 | -5.89 | -4.93 | -8.87 | -23.28 | |
Graham Net | 0 | 0 | -0.01 | -0.01 | -0.04 | |
Working capital | 176.34K | -47.72K | 12.55K | -882.39K | -4.33M | |
Tangible asset value | 191.5K | 41.06K | -57.5K | -791.53K | -4.24M | |
Net current asset value | 176.34K | -94K | -127.79K | -1.13M | -4.52M | |
Invested capital | 0 | 0.3 | 0.56 | -0.93 | -0.77 | |
Average receivables | 80.3K | 80.3K | 0 | 0 | 0 | |
Average payables | 389.02K | 304.17K | 496.99K | 580.14K | 844.51K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 31.55K | 0 | 0 | 0 | 0 | |
Days payables outstanding | 39.62 | 112.28 | 82.43 | 70.09 | 125.56 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0.01 | 0 | 0 | 0 | 0 | |
Payables turnover | 9.21 | 3.25 | 4.43 | 5.21 | 2.91 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -5.49 | -8.6 | -15.53 | 17.74 | 1.86 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q4
Metric | History | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 | |
Operating cash flow per share | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | |
Free cash flow per share | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | |
Cash per share | 0 | 0 | 0 | 0 | 0 | |
Book value per share | 0 | -0.01 | -0.02 | -0.03 | -0.03 | |
Tangible book value per share | -0.01 | -0.01 | -0.02 | -0.03 | -0.04 | |
Share holders equity per share | 0 | -0.01 | -0.02 | -0.03 | -0.03 | |
Interest debt per share | 0 | 0.01 | 0.01 | 0.02 | 0.02 | |
Market cap | 111.25M | 229.25M | 46.47M | 19.77M | 76.14M | |
Enterprise value | 111.5M | 229.87M | 47.92M | 21.97M | 78.96M | |
P/E ratio | -15.3 | -23.78 | -7.48 | -4.55 | -10.68 | |
Price to sales ratio | -701.03 | 28.99K | 4.49K | 951.98 | 3.76K | |
POCF ratio | -111.81 | -203.27 | -49.59 | -22.02 | -127.26 | |
PFCF ratio | -111.72 | -202.96 | -49.59 | -22.02 | -126.97 | |
P/B Ratio | -327.08 | -339.38 | -26.34 | -6.78 | -20.75 | |
PTB ratio | -327.08 | -339.38 | -26.34 | -6.78 | -20.75 | |
EV to sales | -702.61 | 29.07K | 4.63K | 1.06K | 3.9K | |
Enterprise value over EBITDA | -61.34 | -95.49 | -30.86 | -20.27 | -53.45 | |
EV to operating cash flow | -112.06 | -203.82 | -51.14 | -24.47 | -131.97 | |
EV to free cash flow | -111.97 | -203.51 | -51.14 | -24.47 | -131.67 | |
Earnings yield | -0.02 | -0.01 | -0.03 | -0.05 | -0.02 | |
Free cash flow yield | -0.01 | 0 | -0.02 | -0.05 | -0.01 | |
Debt to equity | -0.93 | -1.07 | -0.92 | -0.78 | -0.77 | |
Debt to assets | 0.28 | 0.59 | 1.4 | 2.24 | 3.27 | |
Net debt to EBITDA | -0.14 | -0.26 | -0.93 | -2.04 | -1.91 | |
Current ratio | 0.28 | 0.18 | 0.14 | 0.03 | 0 | |
Interest coverage | 0 | 0 | 0 | -525.41 | 0 | |
Income quality | 0.55 | 0.47 | 0.6 | 0.83 | 0.34 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | -11.6 | 305.81 | 151.12 | 53.19 | 72.8 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 1.92 | |
Intangibles to total assets | 0.4 | 0.56 | 0.58 | 0.63 | 0.66 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0.01 | -0.21 | 0 | 0 | -0.07 | |
Capex to depreciation | -5.25 | -0.63 | 0 | 0 | -0.04 | |
Stock based compensation to revenue | -4.25 | 138.48 | 0 | -11.69 | 36.91 | |
Graham number | 0.04 | 0.05 | 0.07 | 0.07 | 0.1 | |
ROIC | 15.05 | -6.91 | -11.18 | 2.93 | 2.59 | |
Return on tangible assets | -2.67 | -4.43 | -3.17 | -2.87 | -6.07 | |
Graham Net | -0.01 | -0.02 | -0.02 | -0.03 | -0.04 | |
Working capital | -882.39K | -1.01M | -1.15M | -3.6M | -4.33M | |
Tangible asset value | -791.53K | -1.36M | -2.43M | -3.56M | -4.24M | |
Net current asset value | -1.13M | -1.67M | -2.73M | -3.84M | -4.52M | |
Invested capital | -0.93 | -1.07 | -0.92 | -0.78 | -0.77 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 518.83K | 0 | 651.96K | 1.08M | 973.33K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 278.95 | 162 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0.32 | 0.56 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 5.34 | 3.57 | 0.88 | 0.37 | 0.49 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
MDXL Frequently Asked Questions
What is MediXall Group, Inc. stock symbol ?
MediXall Group, Inc. is a US stock , located in Fort lauderdale of Fl and trading under the symbol MDXL
What is MediXall Group, Inc. stock quote today ?
MediXall Group, Inc. stock price is $0.0004 today.
Is MediXall Group, Inc. stock public?
Yes, MediXall Group, Inc. is a publicly traded company.